Granzyme B degradation by autophagy decreases tumor cell susceptibility to natural killer-mediated lysis under hypoxia

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 43, 2013, Pages 17450-17455

  Baginska, Joanna ^a   Viry, Elodie ^a   Berchem, Guy ^a   Poli, Aurélie ^a   Noman, Muhammad Zaeem ^b   Van Moer, Kris ^a   Medves, Sandrine ^a   Zimmer, Jacques ^a   Oudin, Anaïs ^a   Niclou, Simone P ^a   Bleackley, R Chris ^c   Goping, Ing Swie ^c   Chouaib, Salem ^b   Janji, Bassam ^a  

^a Public Research Center for Health   (Luxembourg)

^b INSERM   (France)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Breast adenocarcinoma; Hypoxic tumor microenvironment; Immunotherapy; Innate immunity

Indexed keywords

BECLIN 1; GRANZYME B;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; AUTOPHAGOSOME; AUTOPHAGY; BREAST CANCER; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; ENZYMATIC DEGRADATION; FEMALE; HUMAN; HUMAN CELL; HYPOXIC CELL; IN VITRO STUDY; IN VIVO STUDY; LYSIS; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; TARGET CELL; TUMOR CELL; TUMOR REGRESSION;

BREAST ADENOCARCINOMA; HYPOXIC TUMOR MICROENVIRONMENT; IMMUNOTHERAPY; INNATE IMMUNITY;

ANIMALS; APOPTOSIS REGULATORY PROTEINS; AUTOPHAGY; CELL HYPOXIA; CELL LINE, TUMOR; CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; FLOW CYTOMETRY; GRANZYMES; HUMANS; IMMUNOBLOTTING; KILLER CELLS, NATURAL; MCF-7 CELLS; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICROSCOPY, CONFOCAL; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; PHAGOSOMES; TIME-LAPSE IMAGING; TRANSPLANTATION, HETEROLOGOUS; TUMOR BURDEN;

EID: 84886377822     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1304790110     Document Type: Article

References (35)

1. Zitvogel L, Tesniere A, Kroemer G (2006) Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 6(10):715-727.
2. Whiteside TL (2008) The tumor microenvironment and its role in promoting tumor growth. Oncogene 27(45):5904-5912.
3. Swartz MA, et al. (2012) Tumor microenvironment complexity: Emerging roles in cancer therapy. Cancer Res 72(10):2473-2480.
4. Smyth MJ, Hayakawa Y, Takeda K, Yagita H (2002) New aspects of natural-killer-cell surveillance and therapy of cancer. Nat Rev Cancer 2(11):850-861.
5. Bryceson YT, March ME, Ljunggren HG, Long EO (2006) Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. Blood 107(1):159-166.
6. Smyth MJ, et al. (2000) Differential tumor surveillance by natural killer (NK) and NKT cells. J Exp Med 191(4):661-668.
7. Lv L, et al. (2011) The accumulation and prognosis value of tumor infiltrating IL-17 producing cells in esophageal squamous cell carcinoma. PLoS ONE 6(3):e18219.
8. van Herpen CM, et al. (2005) Intratumoral recombinant human interleukin-12 administration in head and neck squamous cell carcinoma patients modifies locoregional lymph node architecture and induces natural killer cell infiltration in the primary tumor. Clin Cancer Res 11(5):1899-1909.
9. Ishigami S, et al. (2000) Prognostic value of intratumoral natural killer cells in gastric carcinoma. Cancer 88(3):577-583.
10. Ménard C, et al. (2009) Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients. Cancer Res 69(8):3563-3569.
11. Stanietsky N, Mandelboim O (2010) Paired NK cell receptors controlling NK cytotoxicity. FEBS Lett 584(24):4895-4900.
12. Stern-Ginossar N, Mandelboim O (2009) An integrated view of the regulation of NKG2D ligands. Immunology 128(1):1-6.
13. Kärre K, Ljunggren HG, Piontek G, Kiessling R (2005) Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. 1986. J Immunol 174(11):6566-6569.
14. Campoli M, Ferrone S (2008) Tumor escape mechanisms: Potential role of soluble HLA antigens and NK cells activating ligands. Tissue Antigens 72(4):321-334.
15. Lee CT, Mace T, Repasky EA (2010) Hypoxia-driven immunosuppression: A new reason to use thermal therapy in the treatment of cancer? Int J Hyperthermia 26(3):232-246.
16. Noman MZ, et al. (2011) Blocking hypoxia-induced autophagy in tumors restores cytotoxic T-cell activity and promotes regression. Cancer Res 71(18):5976-5986.
17. Bosco MC, Varesio L (2012) Dendritic cell reprogramming by the hypoxic environment. Immunobiology 217(12):1241-1249.
18. Youssef MM, Symonds P, Ellis IO, Murray JC (2006) EMAP-II-dependent lymphocyte killing is associated with hypoxia in colorectal cancer. Br J Cancer 95(6):735-743.
19. Chouaib S, et al. (2012) Hypoxia promotes tumor growth in linking angiogenesis to immune escape. Front Immunol 3:21.
20. Grimshaw MJ, Naylor S, Balkwill FR (2002) Endothelin-2 is a hypoxia-induced autocrine survival factor for breast tumor cells. Mol Cancer Ther 1(14):1273-1281.
21. Sceneay J, et al. (2012) Primary tumor hypoxia recruits CD11b+/Ly6Cmed/Ly6G+ immune suppressor cells and compromises NK cell cytotoxicity in the premetastatic niche. Cancer Res 72(16):3906-3911.
22. Flavell RA, Sanjabi S, Wrzesinski SH, Licona-Limón P (2010) The polarization of immune cells in the tumour environment by TGFbeta. Nat Rev Immunol 10(8):554-567.
23. Siemens DR, et al. (2008) Hypoxia increases tumor cell shedding of MHC class I chainrelated molecule: Role of nitric oxide. Cancer Res 68(12):4746-4753.
24. Noman MZ, Janji B, Berchem G, Mami-Chouaib F, Chouaib S (2012) Hypoxia-induced autophagy: A new player in cancer immunotherapy? Autophagy 8(4):704-706.
25. Michaud M, et al. (2011) Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 334(6062):1573-1577.
26. Heppner GH, Miller FR, Shekhar PM (2000) Nontransgenic models of breast cancer. Breast Cancer Res 2(5):331-334.
27. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: The next generation. Cell 144(5):646-674.
28. Ljunggren HG, Malmberg KJ (2007) Prospects for the use of NK cells in immunotherapy of human cancer. Nat Rev Immunol 7(5):329-339.
29. Wildenberg ME, et al. (2012) Autophagy attenuates the adaptive immune response by destabilizing the immunologic synapse. Gastroenterology 142(7):1493-1503.
30. Wowk ME, Trapani JA (2004) Cytotoxic activity of the lymphocyte toxin granzme B. Microbes Infect 6(8):752-758.
31. Gross C, Koelch W, DeMaio A, Arispe N, Multhoff G (2003) Cell surface-bound heat shock protein 70 (Hsp70) mediates perforin-independent apoptosis by specific binding and uptake of granzyme B. J Biol Chem 278(42):41173-41181.
32. Lopez JA, Brennan AJ, Whisstock JC, Voskoboinik I, Trapani JA (2012) Protecting a serial killer: Pathways for perforin trafficking and self-defence ensure sequential target cell death. Trends Immunol 33(8):406-412.
33. Thiery J, et al. (2011) Perforin pores in the endosomal membrane trigger the release of endocytosed granzyme B into the cytosol of target cells. Nat Immunol 12(8): 770-777.
34. Longatti A, Tooze SA (2012) Recycling endosomes contribute to autophagosome formation. Autophagy 8(11):1682-1683.
35. Ciccone E, et al. (1995) General role of HLA class I molecules in the protection of target cells from lysis by natural killer cells: evidence that the free heavy chains of class I molecules are not sufficient to mediate the protective effect. Int Immunol 7(3): 393-400.